MentionFox
Home › Executive changes › NRX Pharmaceuticals, Inc.
Leadership changes · NRXP · SEC Form 8-K, Item 5.02

Leadership changes at NRX Pharmaceuticals, Inc. (2026)

Before you join, sell to or invest in NRX Pharmaceuticals, Inc.

MentionFox check on NRX Pharmaceuticals, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/nrx-pharmaceuticals

Check NRX Pharmaceuticals, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about NRX Pharmaceuticals, Inc.?

Who joined and who left NRX Pharmaceuticals, Inc. (NRXP)? 1 appointment reported on 2026-02-02, each cited to the company's own filing.

Joseph M. Casper was named Chief Operating Officer of NRX Pharmaceuticals, Inc., effective January 27, 2026. As of November 14, 2026, NRX Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 2, 2026, naming 1 appointment (Form 8-K, February 2, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

The B Group, Inc. also filed stake reports on 1 other company ↓

Sell to companies like NRX Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-02-02

NRX Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-02. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as NRX Pharmaceuticals, Inc. files it.

Also on the record for NRX Pharmaceuticals, Inc.

DateRecordFigureOur pageSource
May 15, 2026Stake report, Schedule 13G/A, by Anson Funds Management LP4.9% of the class5%+ stakesSource
August 21, 2025Stake report, Schedule 13G, by The B Group, Inc.12.62% of the class5%+ stakesSource
August 14, 2025Stake report, Schedule 13G/A, by Anson Funds Management LP9.3% of the class5%+ stakesSource
March 7, 2025Form D, private offering$3.50M soldForm D pageSource

Selling to them or working with them? See who runs NRX Pharmaceuticals, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on NRX Pharmaceuticals, Inc. and the records around it.

NRX Pharmaceuticals, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on NRX Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on NRX Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on NRX Pharmaceuticals, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    5 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-02InChief Operating Officer2026-01-278-K, 2026-02-02

Who leads NRX Pharmaceuticals, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to NRX Pharmaceuticals, Inc.?

New leaders reset buying decisions — get the Full Report on NRX Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch NRX Pharmaceuticals, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Operating Officer at NRX Pharmaceuticals, Inc., with the record behind each one.

Find candidates like Chief Operating Officer at NRX Pharmaceuticals, Inc.

Every change, in the filing's words

Filed 2026-02-02 · 8-K

Appointed: Joseph M. Casper, Chief Operating Officer, effective 2026-01-27

On January 27, 2026, the Board of Directors of the Company appointed Joseph M. Casper, age 75, as the Chief Operating Officer of the Company, effective January 27, 2026.

Also stated in this filing

  • Mr. Casper brings 35 years of experience in the healthcare industry to the Company's leadership team.
  • Prior to joining the Company, Mr. Casper has held various senior leadership positions.
  • Mr. Casper has served in consulting leadership positions with Deloitte and First Consulting Group, where he advised large organizations and academic medical centers.
  • His professional experience also includes work with major payer and provider organizations, including Kaiser Permanente and Anthem.
  • He also worked extensively with academic medical centers such as the University Medical Center, Cleveland, Ohio.
  • Mr. Casper is the co-inventor of an early medical record aggregation platform that ultimately scaled to serve more than 15 million patients.
  • Between 2016 to 2021, he served on the board of directors of Ingine Inc., a healthcare artificial intelligence company.
  • Since 2019, he has been serving on the board of directors of ThriveWell Tech, a company focused on senior living technologies.
  • Further, since 2021, he has been serving on the board of directors of Touro University, supporting physician and nursing education through its Colleges of Osteopathic Medicine and Health and Human Services.

Tools for this story

Each opens in a new tab, filled in for NRX Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/nrx-pharmaceuticals
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined NRX Pharmaceuticals, Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/nrx-pharmaceuticals